Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage: A Case Series

Mary S. Baker, Khalil Diab, William Carlos, Praveen Mathur

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background:The diffuse alveolar hemorrhage (DAH) syndrome is a life-threatening pulmonary complication related to systemic vasculitides, posthematopoietic stem cell transplantation, drugs, or toxins. Once DAH develops, the mortality rate is as high as 50% to 80%. Initial treatment consists of high-dose steroids and supportive measures, including mechanical ventilation. We present a case series of 6 patients treated with intrapulmonary recombinant factor VIIa (rFVIIa) to treat refractory DAH.Methods:Six patients with DAH were treated with intrapulmonary instillation of rFVIIa. Doses were divided equally between the right and the left lungs. Doses were 30, 50, or 60 mcg/kg and frequencies varied from a single administration to repeated doses on subsequent days on the basis of the clinical response. All patients received high-dose steroids, and 4 also received an aminocaproic acid infusion.Results:Intrapulmonary rVFIIa treated DAH effectively in 5 of 6 patients. Doses used were smaller and less frequent than those described previously.Conclusions:Intrapulmonary factor VII is an effective adjunctive treatment for DAH. We achieved treatment success with both smaller and less frequent doses than those described previously. This may be a good therapeutic option for DAH, particularly when standard therapies have failed or bleeding is immediately life threatening. It is possible that intrapulmonary rFVIIa could save costs, while improving the intensive care unit length of stay. Further prospective studies are needed to assess the optimal dose and frequency for adequate therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalJournal of Bronchology and Interventional Pulmonology
Volume23
Issue number3
DOIs
StatePublished - Jul 1 2016

Fingerprint

Factor VII
Hemorrhage
Therapeutics
Steroids
Aminocaproic Acid
Systemic Vasculitis
Lung
Stem Cell Transplantation
Artificial Respiration
Intensive Care Units
Length of Stay
Prospective Studies
Costs and Cost Analysis
Mortality

Keywords

  • diffuse alveolar hemorrhage
  • hematopoietic stem cell transplant
  • recombinant factor VII

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage : A Case Series. / Baker, Mary S.; Diab, Khalil; Carlos, William; Mathur, Praveen.

In: Journal of Bronchology and Interventional Pulmonology, Vol. 23, No. 3, 01.07.2016, p. 255-258.

Research output: Contribution to journalArticle

@article{8a29a3165cd9480b8be403b3ad050fc9,
title = "Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage: A Case Series",
abstract = "Background:The diffuse alveolar hemorrhage (DAH) syndrome is a life-threatening pulmonary complication related to systemic vasculitides, posthematopoietic stem cell transplantation, drugs, or toxins. Once DAH develops, the mortality rate is as high as 50{\%} to 80{\%}. Initial treatment consists of high-dose steroids and supportive measures, including mechanical ventilation. We present a case series of 6 patients treated with intrapulmonary recombinant factor VIIa (rFVIIa) to treat refractory DAH.Methods:Six patients with DAH were treated with intrapulmonary instillation of rFVIIa. Doses were divided equally between the right and the left lungs. Doses were 30, 50, or 60 mcg/kg and frequencies varied from a single administration to repeated doses on subsequent days on the basis of the clinical response. All patients received high-dose steroids, and 4 also received an aminocaproic acid infusion.Results:Intrapulmonary rVFIIa treated DAH effectively in 5 of 6 patients. Doses used were smaller and less frequent than those described previously.Conclusions:Intrapulmonary factor VII is an effective adjunctive treatment for DAH. We achieved treatment success with both smaller and less frequent doses than those described previously. This may be a good therapeutic option for DAH, particularly when standard therapies have failed or bleeding is immediately life threatening. It is possible that intrapulmonary rFVIIa could save costs, while improving the intensive care unit length of stay. Further prospective studies are needed to assess the optimal dose and frequency for adequate therapeutic efficacy.",
keywords = "diffuse alveolar hemorrhage, hematopoietic stem cell transplant, recombinant factor VII",
author = "Baker, {Mary S.} and Khalil Diab and William Carlos and Praveen Mathur",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/LBR.0000000000000286",
language = "English (US)",
volume = "23",
pages = "255--258",
journal = "Journal of Bronchology and Interventional Pulmonology",
issn = "1944-6586",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage

T2 - A Case Series

AU - Baker, Mary S.

AU - Diab, Khalil

AU - Carlos, William

AU - Mathur, Praveen

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background:The diffuse alveolar hemorrhage (DAH) syndrome is a life-threatening pulmonary complication related to systemic vasculitides, posthematopoietic stem cell transplantation, drugs, or toxins. Once DAH develops, the mortality rate is as high as 50% to 80%. Initial treatment consists of high-dose steroids and supportive measures, including mechanical ventilation. We present a case series of 6 patients treated with intrapulmonary recombinant factor VIIa (rFVIIa) to treat refractory DAH.Methods:Six patients with DAH were treated with intrapulmonary instillation of rFVIIa. Doses were divided equally between the right and the left lungs. Doses were 30, 50, or 60 mcg/kg and frequencies varied from a single administration to repeated doses on subsequent days on the basis of the clinical response. All patients received high-dose steroids, and 4 also received an aminocaproic acid infusion.Results:Intrapulmonary rVFIIa treated DAH effectively in 5 of 6 patients. Doses used were smaller and less frequent than those described previously.Conclusions:Intrapulmonary factor VII is an effective adjunctive treatment for DAH. We achieved treatment success with both smaller and less frequent doses than those described previously. This may be a good therapeutic option for DAH, particularly when standard therapies have failed or bleeding is immediately life threatening. It is possible that intrapulmonary rFVIIa could save costs, while improving the intensive care unit length of stay. Further prospective studies are needed to assess the optimal dose and frequency for adequate therapeutic efficacy.

AB - Background:The diffuse alveolar hemorrhage (DAH) syndrome is a life-threatening pulmonary complication related to systemic vasculitides, posthematopoietic stem cell transplantation, drugs, or toxins. Once DAH develops, the mortality rate is as high as 50% to 80%. Initial treatment consists of high-dose steroids and supportive measures, including mechanical ventilation. We present a case series of 6 patients treated with intrapulmonary recombinant factor VIIa (rFVIIa) to treat refractory DAH.Methods:Six patients with DAH were treated with intrapulmonary instillation of rFVIIa. Doses were divided equally between the right and the left lungs. Doses were 30, 50, or 60 mcg/kg and frequencies varied from a single administration to repeated doses on subsequent days on the basis of the clinical response. All patients received high-dose steroids, and 4 also received an aminocaproic acid infusion.Results:Intrapulmonary rVFIIa treated DAH effectively in 5 of 6 patients. Doses used were smaller and less frequent than those described previously.Conclusions:Intrapulmonary factor VII is an effective adjunctive treatment for DAH. We achieved treatment success with both smaller and less frequent doses than those described previously. This may be a good therapeutic option for DAH, particularly when standard therapies have failed or bleeding is immediately life threatening. It is possible that intrapulmonary rFVIIa could save costs, while improving the intensive care unit length of stay. Further prospective studies are needed to assess the optimal dose and frequency for adequate therapeutic efficacy.

KW - diffuse alveolar hemorrhage

KW - hematopoietic stem cell transplant

KW - recombinant factor VII

UR - http://www.scopus.com/inward/record.url?scp=84979239875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979239875&partnerID=8YFLogxK

U2 - 10.1097/LBR.0000000000000286

DO - 10.1097/LBR.0000000000000286

M3 - Article

C2 - 27261934

AN - SCOPUS:84979239875

VL - 23

SP - 255

EP - 258

JO - Journal of Bronchology and Interventional Pulmonology

JF - Journal of Bronchology and Interventional Pulmonology

SN - 1944-6586

IS - 3

ER -